nucleosid
nucleotid
analog
play
signific
role
antivir
therapi
valu
impress
potenc
high
barrier
resist
approv
treatment
herp
simplex
hiv
hbv
hcv
influenza
new
drug
develop
treatment
rsv
ebola
coronaviru
mer
emerg
virus
howev
class
compound
also
experienc
high
attrit
rate
clinic
trial
due
toxic
review
discuss
util
differ
biochem
cellbas
assay
provid
recommend
assess
toxic
liabil
enter
anim
toxic
studi
nucleosid
analog
first
studi
antimetabolit
georg
hitch
gertrud
elion
work
led
discoveri
treatment
leukemia
gout
hyperuricemia
parasit
protozoan
infect
well
immunosuppress
organ
transplant
effort
pave
way
discoveri
seri
nucleosid
analog
antitumor
agent
arac
gemcitabin
figur
still
use
today
mani
antitumor
nucleosid
analog
show
antivir
activ
none
possess
adequ
clinic
safeti
profil
antivir
use
acyclovir
figur
discov
treatment
herp
simplex
viru
hsv
infect
breakthrough
start
new
era
antivir
therapi
acyclovir
remark
safeti
profil
stem
two
properti
activ
compound
monophosph
mp
occur
virusinfect
cell
sinc
process
reli
viral
thymidin
kinas
acyclovir
tp
select
inhibit
viral
dna
polymeras
host
dna
polymeras
follow
gener
hsv
nucleosid
antivir
penciclovir
ganciclovir
figur
prodrug
develop
improv
potenc
resist
profil
hivaid
epidem
present
unpreced
demand
effect
antivir
azidothymidin
azt
zidovudin
figur
chaintermin
inhibitor
revers
transcriptas
rt
approv
signifi
first
step
toward
control
devast
diseas
first
gener
nucleosid
analog
hiv
efficaci
compound
also
show
consider
toxic
includ
cardiomyopathi
azt
ddi
ddc
figur
peripher
neuropathi
ddi
ddc
sensorineur
deaf
ddc
lactic
acidosi
azt
ddi
diabet
ddi
cytopenia
azt
toxic
ddc
azt
associ
inhibit
mitochondria
dna
synthesi
cell
cultur
patient
tissu
sampl
later
detail
kinet
studi
hiv
nucleosid
use
recombin
human
mitochondri
dna
polymeras
pol
c
demonstr
import
select
inhibit
ontarget
rt
offtarget
human
pol
c
unfortun
knowledg
came
year
late
inform
phase
ii
clinic
trial
fiau
patient
infect
hbv
patient
develop
sever
liver
toxic
lactic
acidosi
patient
die
followup
biochem
cellular
vivo
studi
show
fiau
readili
incorpor
mitochondri
dna
lead
decreas
mtdna
abund
thu
render
mitochondria
dysfunct
preval
mitochondri
toxic
associ
deoxi
nucleosid
analog
led
fda
recommend
test
drug
candid
set
mitochondri
toxic
assay
includ
pol
c
inhibit
lactic
acid
format
mitochondri
dna
content
glucos
util
use
test
secondgener
antivir
nucleosidetid
analog
ftc
tenofovir
shown
poor
substrat
pol
c
demonstr
significantli
improv
clinic
safeti
profil
despit
collect
knowledg
nucleosid
analogassoci
mitochondri
toxic
safeti
concern
continu
discoveri
hcv
antivir
number
hcv
nucleosidetid
analog
fail
phase
ii
due
toxic
associ
toxic
analog
includ
valopicitabin
gastrointestin
toxic
figur
balapiravir
hematolog
toxic
figur
cardiac
kidney
toxic
figur
clinic
hold
due
associ
figur
liver
toxic
figur
except
tp
form
compound
substrat
mitochondri
rna
polymeras
polrmt
balapiravir
specif
mitochondria
toxin
inhibit
polrmt
reduc
mitochondri
protein
synthesi
eventu
decreas
mitochondri
respir
data
show
cmegtp
incorpor
rna
polrmt
decreas
mitochondria
protein
synthesi
decreas
mitochondri
cellular
respir
furthermor
jin
et
al
demonstr
toxic
directli
correl
cmegmp
nucleotid
moieti
rather
naphthalenephosphorylamino
propano
prodrug
moieti
interestingli
compar
select
mitochondria
inhibitor
ddc
chloramphenicol
figur
inhibit
profil
distinctli
differ
mitochondri
protein
synthesi
respir
indic
may
hit
offtarget
rna
polymeras
today
approv
nucleotid
prodrug
treatment
hcv
sofosbuvir
figur
f
cme
uridin
prodrug
well
toler
patient
tp
form
sofosbuvir
show
inhibit
human
polymeras
test
poor
substrat
polrmt
relev
polrmt
inhibit
marker
nucleotid
toxic
support
work
multipl
group
clear
outlier
f
cme
guanosin
prodrug
show
liver
toxic
clinic
trial
poor
substrat
polmrt
show
toxic
vitro
studi
conduct
far
host
polymeras
gener
regard
primari
offtarget
class
compound
howev
observ
toxic
tend
highli
unpredict
may
attribut
complex
uptak
distribut
accumul
differ
compound
differ
organ
exampl
three
close
relat
analog
fiau
fmau
fiac
figur
show
distinctli
differ
toxic
anim
human
fiau
show
toxic
nonclin
anim
speci
includ
mice
rat
dog
monkey
conflict
toxic
find
two
separ
studi
woodchuck
contrast
fiauinduc
hepatotox
observ
clinic
trial
week
beyond
potenti
much
lower
exposur
anim
model
addit
fmau
metabolit
fiau
test
phase
clinic
trial
treatment
murin
leukemia
caus
sever
neurolog
toxic
two
death
among
eight
patient
day
treatment
toxic
primarili
hematopoiet
observ
fiac
cytidin
analog
known
metabol
precursor
fiau
use
treat
hsv
vesicular
stomat
viru
infect
interestingli
recent
hcv
nucleotid
antivir
eg
also
known
figur
livertarget
nucleotid
prodrug
administr
result
liver
toxic
show
cardiovascular
renal
toxic
worthwhil
mention
antivir
nucleosid
could
also
exert
toxic
disrupt
natur
ntp
pool
azt
show
modest
inhibit
mitochondri
dna
polymeras
competit
inhibitor
thymidin
kinas
phosphoryl
thymidin
tmp
ribavirin
poor
substrat
mitochondri
rna
polymeras
reduc
size
guanosin
triphosph
gtp
pool
via
inhibit
inosin
mp
dehydrogenas
one
might
expect
mani
possibl
way
nucleosidetid
analog
elicit
toxic
still
beyond
knowledg
review
focu
host
polymeras
mechanismbas
toxic
summar
differ
biochem
cellular
assay
evalu
potenti
toxic
liabil
strength
limit
method
nucleosidetid
analog
need
transform
exert
ontarget
offtarget
effect
tp
form
necessari
elucid
mechan
tabl
typic
initi
enzymat
assay
polymeras
radioactivitybas
polymer
assay
inhibit
nucleotid
measur
ic
valu
inhibit
ic
assay
easili
adapt
filter
bind
assay
multipl
compound
access
simultan
howev
base
inhibit
studi
alon
one
establish
whether
nucleotid
actual
incorpor
therefor
singl
nucleotid
incorpor
sni
assay
particularli
use
determin
ntp
analog
actual
serv
substrat
polymeras
high
concentr
ntp
analog
eg
mm
ribos
nucleotid
tp
rntp
mm
deoxyribos
nucleotid
tp
dntp
rel
rate
incorpor
analog
compar
natur
ntp
counterpart
mechanist
insight
presteadi
state
kinet
analysi
ntp
incorpor
offer
detail
kinet
paramet
presteadi
state
polymer
rate
constant
k
pol
ntp
dissoci
constant
k
studi
incorpor
rate
studi
use
multipl
time
point
nucleotid
concentr
often
use
quenchflow
techniqu
make
studi
reagentand
timeconsum
final
mechan
nucleotid
analogderiv
enzym
inhibit
reveal
elong
assay
stabl
elong
complex
form
incorpor
next
natur
ntp
measur
normal
ntp
analog
character
one
three
group
chaintermin
delay
chaintermin
stabli
incorpor
analog
stabli
incorpor
ntp
analog
difficult
studi
toxic
could
lead
littl
quantit
chang
dna
rna
protein
express
qualiti
abovement
biochem
assay
reli
heavili
avail
high
qualiti
tp
activ
form
timeand
resourceconsum
synthes
tp
salt
subject
degrad
overtim
time
certain
inorgan
contamin
could
lead
appar
inhibit
polymeras
due
mechan
action
nucleosid
analog
gener
evalu
day
replic
laboratoryadapt
cell
line
nonrepl
primari
cell
standard
readout
effect
compound
atp
level
within
cell
found
among
laboratoryadapt
cell
test
prostat
cancerderiv
cell
tcell
leukemiaderiv
cell
gener
sensit
toxin
significantli
sensit
cell
wide
use
cell
line
vitro
toxic
studi
addit
found
laboratoryadapt
cell
use
detect
potenti
toxic
liabil
primari
cell
certain
case
test
specif
cell
assay
warrant
exampl
number
firstgener
hiv
nucleosid
analog
show
myelosuppress
effect
result
fda
recommend
evalu
toxic
growth
human
bone
marrow
progenitor
cell
coloni
format
assay
import
measur
cellular
tp
level
nucleosidetid
analog
cytotox
often
directli
relat
cellular
level
activ
tp
metabolit
cme
guanosin
nucleotid
prodrug
former
form
higher
tp
correl
significantli
higher
toxic
nucleosid
analog
poorli
phosphoryl
cell
balapiravir
even
though
specif
inhibitor
polrmt
balapiravir
show
littl
toxic
larg
panel
cell
line
primari
cell
test
develop
compound
stop
phase
ii
due
toxic
shown
tabl
employ
three
mitochondriafocus
cellbas
assay
evalu
potenti
mitochondri
toxic
mitochondri
dna
content
assay
wide
use
studi
deoxi
nucleosid
analog
assess
effect
ribos
nucleosidetid
analog
mitochrondri
rna
synthesi
ddc
serv
good
posit
control
cell
seem
ideal
cell
line
assay
mitochondri
protein
synthesi
assay
use
evalu
ribonucleosidetid
analog
assay
level
two
protein
measur
simultan
mitochondri
dnaencod
protein
cytochrom
c
oxidas
nuclear
dnaencod
protein
succin
dehydrogenas
sdha
data
analysi
found
compar
individu
level
sdha
protein
untreat
dmso
control
yield
reproduc
data
use
ratio
sdha
chloramphenicol
specif
inhibitor
mitochondri
protein
synthesi
use
posit
control
sinc
mitochondri
respir
regard
gold
standard
measur
mitochondri
function
use
extens
studi
mitochondri
toxin
directli
impair
electron
transport
chain
use
studi
nucleosidetid
analog
recent
assay
provid
sensit
function
readout
requir
knowledg
mechan
action
complet
loss
mitochondri
respir
capac
detect
chang
cellular
atp
level
phenomenon
observ
inhibitor
divers
molecular
target
includ
ddc
inhibitor
mitochondri
dna
synthesi
azido
cytidin
inhibitor
mitochondri
rna
synthesi
chloramphenicol
inhibitor
mitochondri
protein
synthesi
compound
show
mitochondri
gener
toxic
method
make
possibl
identifi
whether
mitochondria
toxic
occur
lower
drug
concentr
mitochondri
protein
respir
assay
found
cell
offer
higher
sensit
reproduc
cell
assay
limit
predict
valu
glucosegalactos
cc
assay
face
mitochondria
damag
cell
known
switch
glycolysi
gener
atp
therefor
glucosegalactos
cc
assay
wide
use
detect
mitochondria
toxic
absenc
glucos
galactoseadapt
cell
forc
reli
heavili
mitochondri
oxpho
thu
would
show
decreas
cc
howev
predict
assay
challeng
hyne
report
show
assay
detect
potenti
mitochondri
toxin
test
even
though
nucleosidetid
analog
includ
hyne
studi
consist
find
test
clinic
relev
nucleosidetid
analog
none
known
mitochondri
toxin
ddc
fiau
azido
c
show
enhanc
cytotox
galactoseadapt
cell
research
develop
signific
number
nucleosidetid
analog
termin
preclin
stage
due
toxic
anim
model
though
report
mitochondri
toxic
indic
suspect
date
due
number
factor
outlin
mitochondri
toxic
difficult
detect
anim
speci
correl
human
best
tenuou
potenti
anim
model
genet
mitochondri
abnorm
human
anim
may
sensit
nucleosidetid
toxic
exampl
mice
model
genet
mitochondri
abnorm
heterozyg
superoxid
dismutas
knockout
sod
mice
suscept
mitochondria
toxin
wildtyp
anim
recent
xu
et
al
report
fiauinduc
liver
toxic
chimer
tknog
mice
graft
human
liver
anim
model
like
may
improv
abil
detect
nucleosid
toxic
viral
diseas
vari
greatli
durat
sever
safeti
threshold
antivir
nucleosidetid
need
consid
context
efficaci
treatment
durat
exampl
compound
treat
acut
deadli
viral
infect
ebola
would
like
differ
safeti
criteria
drug
use
control
chronic
infect
hbv
exist
nucleosidetid
routin
screen
emerg
virus
possibl
compound
fail
achiev
adequ
therapeut
window
one
viru
may
suitabl
treat
viral
infect
antivir
nucleosidetid
analog
target
viral
dna
rna
replic
machineri
mechan
make
potenti
inhibitor
host
dna
rna
synthesi
well
especi
mitochondri
dna
rna
synthesi
mitochondri
toxic
manifest
multipl
form
vivo
underli
mani
clinicalstag
failur
difficult
detect
anim
studi
past
year
batteri
vitro
test
mitochondri
toxic
evolv
continu
expand
allow
improv
earli
detect
mitochondri
liabil
drug
molecul
actual
toxic
liabil
assess
fulli
test
anim
toxic
studi
eventu
human
clinic
trial
nevertheless
believ
employ
proper
biochem
cellular
assay
earli
meaning
impact
reduc
preclin
clinic
toxic
liabil
class
compound
